Lynparza
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Keytruda Sales Climb 16 Percent in Q2 as Merck Pursues New Oncology Candidates
The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.
Tango Therapeutics Scraps USP1 Inhibitor Trial Due to Toxicities
In a Phase I/II trial in patients with BRCA1/2-mutated and other HRD-positive solid tumors, TNG348 caused serious liver function abnormalities.
Chinese Trial Suggests PARP, VEGF Inhibitor Combo Benefits Advanced BRCA1/2-Mutant Breast Cancer
Premium
Fuzuloparib, both alone and combined with apatinib, improved patients' progression-free survival versus standard chemotherapy.
PARP Inhibitor, Chemo Combo Shows Potential as Neoadjuvant Option for BRCA-Mutant Breast Cancer
Premium
The PARTNER trial explored a novel dosing schedule for chemo followed by Lynparza two days later that showed promising antitumor activity and tolerability.
Mar 21, 2024
Jan 30, 2024